Market Overview

Myocardial Fibrosis| A Pipeline Molecule Analysis Report 2018| Technavio

Share:

Technavio has announced their latest pipeline analysis report on the myocardial
fibrosis market
. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat myocardial fibrosis.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180725005705/en/

Technavio has published a new report on the drug development pipeline for myocardial fibrosis, inclu ...

Technavio has published a new report on the drug development pipeline for myocardial fibrosis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Myocardial fibrosis: Market overview

Myocardial fibrosis, also known as cardiac fibrosis, is a condition that
involves the impairment of the heart's muscle cells called myocytes. It
belongs to a class of diseases collectively known as fibrosis, which is
defined by the solidifying or scarring of tissue. Myocardial fibrosis
not only affects the heart but also other organs, such as the lungs and
liver.

According to a senior market research analyst at Technavio, "In
myocardial fibrosis, myocytes are replaced by tissue that is unable to
contract. This happens when fibroblasts, which produce collagen to
enable wound healing, generate excessive amounts of the protein. Thus,
the rising incidence of myocardial fibrosis is expected to boost the
drug development for myocardial fibrosis throughout the predicted
period."

Myocardial fibrosis: Segmentation analysis

This pipeline analysis report segments the myocardial fibrosis market
based on therapies employed (monotherapy), RoA (oral, and parenteral),
therapeutic modality (small molecule, protein, peptide, endoglin
antibody, stem cell, and RNA), targets (galectin-3, BMP, collagen, ERβ,
ET-1, methotrexate, NPR-C, Proline tRNA synthetase, RhoA, soluble
epoxide hydrolase, and TGF-β), MoA (galectin-3 inhibitor, BMP inhibitor,
cell replacement, collagen modulator, ERβ agonists, ET-1 agonist,
methotrexate inhibitor, NPR-C agonists, Proline tRNA synthetase
inhibitor, RhoAGEF12 inhibitor, soluble epoxide hydrolase inhibitors,
and TGF-β modulator), and recruitment status (not yet recruiting). It
provides an in-depth analysis of the prominent factors influencing the
market, including drivers, opportunities, trends, and industry-specific
challenges.

Based on therapeutic modality, around 43% of the molecules that are
being investigated for the treatment of myocardial fibrosis are small
molecule.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!